PULSE the living trend engine
🤖 Open Intelligence Dossier available for AI agents & citation View Markdown (.md) →
▲ Peaking Business

Johnson & Johnson looking to buy eye disease biotech for up to $3.4bn

Johnson & Johnson agreed to buy Texas-based biotech Ollin Biosciences for up to $3.33 billion to expand its eye disease therapies.

15sources
20articles
19velocity
+591%since first seen
2d agofirst detected

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

The brief

Johnson & Johnson announced it has agreed to buy the Texas-based biotech Ollin Biosciences for up to $3.33 billion to expand its pipeline of eye disease therapies, according to Endpoints News. The drugmaker stated it will acquire Ollin for $2.2 billion upfront, with the potential for regulatory and commercial milestone payments reaching up to about $1.13 billion. Some reports noted figures up to $3.4 billion, while Yahoo Finance and other outlets cited a Financial Times report mentioning up to $3.4bn.

Established in 2023, Ollin is backed by investment firms ARCH Venture Partners and Mubadala Capital to develop treatments for vision-threatening diseases. Through this acquisition, J&J gains access to an experimental eye disease treatment, boosting its presence in a therapeutic area where it previously maintained a limited footprint despite its large contact lens business. Ollin is developing OLN324, an experimental drug intended to treat diabetic macular edema and wet age-related macular degeneration, which are two leading causes of vision loss.

According to Kip Connor, vice president, ophthalmology disease area stronghold leader at Johnson & Johnson, OLN324 selectively targets two important drivers of retinal disease and has the potential to achieve stronger and more sustained disease control. Ollin reported that in a recent early-stage head-to-head study, the drug showed faster and greater improvements in eye structure and greater vision gains in both diabetic macular edema and wet age-related macular degeneration than Roche's Vabysmo. Ollin's pipeline also includes OLN102, which is currently in preclinical development for thyroid eye disease and Graves' disease.

Ollin previously stated plans to begin late-stage studies testing OLN324 in the second half of this year, having raised $330 million in June to fund those trials. Additionally, Johnson & Johnson said it will enter into a separate agreement with Blackstone Life Sciences. Blackstone will pay $750 million to the drugmaker over multiple years to fund the late-stage development of OLN324, and in turn, Blackstone will be eligible to receive payments and royalties. Endpoints News also noted that last week, Pfizer announced Blackstone would provide up to $1.5 billion through 2028 to help fund the development of an experimental monthly obesity treatment.

Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 22h ago.

Quick answers

How much is Johnson & Johnson paying for Ollin Biosciences?

J&J is paying $2.2 billion upfront, with potential regulatory and commercial milestone payments of up to about $1.13 billion, bringing the total up to $3.33 billion (some reports cite up to $3.4 billion).

What is the main experimental drug being acquired?

J&J is acquiring OLN324, an experimental drug designed to treat diabetic macular edema and wet age-related macular degeneration.

What is Blackstone Life Sciences' role in the deal?

Blackstone will pay $750 million to the drugmaker over multiple years to fund the late-stage development of OLN324 and will receive payments and royalties in return.

Coverage (20)

Topics

Related trends

\n \n \n \n \n \n \n